BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24955709)

  • 1. Novel pancreatic cancer vaccines could unleash the army within.
    Springett GM
    Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
    Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
    J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
    Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
    Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.
    Jhaveri DT; Kim MS; Thompson ED; Huang L; Sharma R; Klein AP; Zheng L; Le DT; Laheru DA; Pandey A; Jaffee EM; Anders RA
    Cancer Immunol Res; 2016 Mar; 4(3):225-33. PubMed ID: 26842750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
    Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
    Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
    Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
    Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
    Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
    World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.
    Schueneman AJ; Sugar EA; Uram J; Bigelow E; Herman JM; Edil BH; Jaffee EM; Zheng L; Laheru DA
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S725-30. PubMed ID: 24046118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
    McCormick KA; Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
    Hum Vaccin Immunother; 2016 Mar; 12(3):563-75. PubMed ID: 26619245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
    Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
    J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for pancreatic cancer.
    Soares KC; Zheng L; Edil B; Jaffee EM
    Cancer J; 2012; 18(6):642-52. PubMed ID: 23187853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
    Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
    J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Therapy in Pancreatic Cancer: Now and the Future?
    Zhang Y; Choi M
    Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
    Koido S; Okamoto M; Shimodaira S; Sugiyama H
    Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
    Le DT; Lutz E; Uram JN; Sugar EA; Onners B; Solt S; Zheng L; Diaz LA; Donehower RC; Jaffee EM; Laheru DA
    J Immunother; 2013 Sep; 36(7):382-9. PubMed ID: 23924790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.